Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer (COLOCROSS)

This study has been completed.
Information provided by (Responsible Party):
Centre Oscar Lambret Identifier:
First received: May 18, 2009
Last updated: July 20, 2012
Last verified: July 2012

The scope of the trial is to determine the preference of patients, after randomization and cross-over, for one of the two treatments.

Another objective of the trial is to assess and compare the safety of each treatment.

Condition Intervention Phase
Colorectal Cancer
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Comparative Study With a Cross-over According to Patients'Preference Receiving Xeloda or UFT With Folinic Acid in Advanced or Metastatic Colo-rectal Cancer

Resource links provided by NLM:

Further study details as provided by Centre Oscar Lambret:

Primary Outcome Measures:
  • patients preference after randomization and cross-over [ Time Frame: after 2 cycles of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • safety of each treatment [ Time Frame: at day 56 (after two cycles of treatment) ] [ Designated as safety issue: Yes ]

Enrollment: 89
Study Start Date: September 2005
Study Completion Date: September 2011
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions

XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days.

Cycle treatment duration : 21 days


Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days.

Duration of treatment cycle : 35 days.

Detailed Description:

Further study details as provided by Centre Oscar Lambret.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Locally advanced or metastatic colo-rectal cancer
  • Age > or = 18 years old
  • PS-WHO < or = 2
  • Polynuclear neutrophil leukocytes > or = 1500/mm3, platelets > or = 100000/mm3
  • Total bilirubin < or = 3 ULN, ASAT-ALAT < or = 2.5 ULN
  • Effective contraception
  • Written informed consent signed

Exclusion Criteria:

  • Concomitant radiotherapy
  • Contraindication to fluoropyrimidines
  • Treatment with sorivudine and its chemical analogs such as brivudine
  • Severe hepatic insufficiency
  • Severe renal insufficiency
  • Pregnant or lactating woman
  • Hypersensitivity to capecitabine, 5FU, tegafur or one of its excipients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00905047

Centre Paul Papin
Angers, France, 49033
Centre Hospitalier
Armentieres, France, 59280
Centre Hospitalier de Béthune
Beuvry, France, 62660
Centre Hospitalier de CHOLET
Cholet, France, 49300
Centre Leonard de Vinci
Dechy, France, 59187
Polyclinique du Bois
Lille, France, 59000
Centre Hospitalier Regional
Lille, France, 59035
Centre Oscar Lambret
Lille, France, 59020
Hopital Saint Vincent de Paul
Lille, France, 59020
Centre Hospitalier
Roubaix, France, 59100
Centre Joliot-Curie
Saint Martin les Boulogne, France, 62280
Centre Hospitalier
Valenciennes, France, 59300
Clinique des Dentellieres
Valenciennes, France, 59300
Sponsors and Collaborators
Centre Oscar Lambret
Principal Investigator: ADENIS Antoine, MD,PhD Centre Oscar Lambret
  More Information

No publications provided

Responsible Party: Centre Oscar Lambret Identifier: NCT00905047     History of Changes
Other Study ID Numbers: COLOCROSS
Study First Received: May 18, 2009
Last Updated: July 20, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Centre Oscar Lambret:
colo-rectal cancer
locally advanced or metastatic colo-rectal cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms by Site
Rectal Diseases
Folic Acid
Growth Substances
Hematologic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Vitamin B Complex
Vitamins processed this record on March 02, 2015